Ovarian Cancer Clinical Trial
Sorafenib With or Without Paclitaxel and Carboplatin in Treating Patients With Recurrent Ovarian Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer
Sorafenib may stop the growth of tumor cells by blocking the enzymes necessary for their growth and by stopping blood flow to the tumor. Drugs used in chemotherapy, such as paclitaxel and carboplatin, work in different ways to stop tumor cells from dividing so they stop growing or die. Giving sorafenib together with chemotherapy may kill more tumor cells. This randomized phase II trial is studying how well giving sorafenib together with paclitaxel and carboplatin works in treating patients with recurrent ovarian cancer, primary peritoneal cancer, or fallopian tube cancer. (Sorafenib only group closed as of 10/10/2008).
PRIMARY OBJECTIVES :
I. Compare the progression-free and overall survival rate of patients with recurrent platinum-sensitive ovarian epithelial, primary peritoneal, or fallopian tube cancer treated with sorafenib with or without carboplatin and paclitaxel. (Arm I [sorafenib only] closed to accrual 10/01/2008) II. Evaluate the response rate and time to disease progression in patients treated with these regimens.
OUTLINE: This is a multicenter study. Patients are stratified according to performance status and participating center.
ARM I (closed to accrual 10/01/2008): Patients receive oral sorafenib twice daily on days 1-28.Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients with disease progression crossover to arm II.
ARM II: Patients receive oral sorafenib twice daily on days 2-19. Patients also receive carboplatin IV over 30 minutes and paclitaxel IV over 3 hours on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
Diagnosis of ovarian epithelial, primary peritoneal, or fallopian tube cancer
Must have received a prior platinum-based regimen
Platinum-sensitive (treatment-free interval > 6 months)
No more than 2 prior chemotherapy regimens
At least 1 unidimensionally measurable lesion >= 20 mm by conventional techniques OR >= 10 mm by spiral CT scan
Not in a prior irradiation field
No known brain metastases
ECOG 0-2 OR
More than 12 weeks
Absolute neutrophil count >= 1,500/mm3
Platelet count >= 100,000/mm3
Hemoglobin >= 9 g/dL
No bleeding diathesis
Bilirubin < 1.5 times upper limit of normal (ULN)
AST or ALT =< 2 times ULN
No history of allergic reaction attributed to compounds of similar chemical or biological composition to sorafenib or other agents used in the study
Patients who have had a reaction to a taxane or a platinum and have not yet been rechallenged may undergo a desensitization regimen on study
No hypersensitivity to paclitaxel or drugs using the vehicle Cremophor El:
Prior hypersensitivity reaction to paclitaxel allowed provided rechallenged successfully
Creatinine < 2 mg/dL
Abnormal cardiac conduction (e.g., bundle branch block or heart block) allowed if stable for the past 6 months
No symptomatic congestive heart failure
No uncontrolled hypertension
No cardiac arrhythmia
No unstable angina pectoris;
No myocardial infarction within the past 6 months
Negative pregnancy test
Fertile patients must use effective contraception
Adequate intestinal function
No concurrent requirements for IV hydration or nutritional support
No active or ongoing infection
No psychiatric illness or social situation that would preclude study compliance
No other concurrent uncontrolled illness
No other invasive malignancy with the past 5 years except nonmelanoma skin cancer
More than 4 weeks since prior chemotherapy (6 weeks for nitrosoureas or mitomycin) and recovered
More than 3 weeks since prior hormonal therapy
More than 4 weeks since prior radiotherapy and recovered
No prior sorafenib
No prior anticancer therapy that contraindicates study therapy
No concurrent cytochrome P450 enzyme-inducing antiepileptic drugs (phenytoin, carbamazepine, or phenobarbital), rifampin, or Hypericum perforatum (St. John's wort)
No concurrent combination antiretroviral therapy for HIV-positive patients
No concurrent therapeutic anticoagulation therapy
Concurrent prophylactic low-dose warfarin allowed for maintenance of venous or arterial access devices
No other concurrent anticancer therapies
No other concurrent investigational agents
Not pregnant or nursing
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There are 4 Locations for this study
Tampa Florida, 33612, United States
Tampa Florida, 33612, United States
Cleveland Ohio, 44106, United States
Mentor Ohio, 44060, United States
Richmond Virginia, 23298, United States
How clear is this clinincal trial information?
Introducing, the Journey Bar
Use this bar to access information about the steps in your cancer journey.